速效型胰島素的全球市場，市場規模和佔有率的分析 - 成長趨勢與預測(2025年～2033年)

速效胰島素市場趨勢及總結

2024年，全球速效胰島素市場規模為77.1億美元，預計2033年將快速成長至117.7億美元，2025年至2033年的複合年增長率為4.81%。

速效胰島素市場成長動力

全球糖尿病盛行率上升

全球糖尿病負擔（尤其是第1型和第2型糖尿病）不斷加重是速效胰島素市場的主要驅動力。根據國際糖尿病聯盟的數據，2023年全球超過5.3億成年人患有糖尿病，預計這一數字還將穩定成長。糖尿病患者數量的增長直接源於對有效的速效胰島素治療的需求增加，這種治療用於控制餐後血糖。隨著越來越多的患者需要精準的胰島素劑量，醫療保健專業人員正在將速效胰島素作為個人化治療計畫的一部分。各國政府和醫療體係也不斷提高對糖尿病的認識，並加大對治療設施的投資，這進一步推動了市場的成長。最近的預測顯示，全球超過5.37億成年人患有糖尿病，預計2045年這一數字將達到7億。

胰島素給藥裝置的進步

胰島素筆、胰島素幫浦和持續血糖監測系統的技術進步大大提高了速效胰島素的便利性和有效性。目前的給藥裝置為患者提供了精準便捷的給藥方式，降低了低血糖風險，並最大限度地控制了血糖。這些發展使得年輕且技術先進的患者擴大採用速效胰島素製劑，也提高了治療順從性。與糖尿病管理應用程式和智慧胰島素筆的兼容性也提高了這些胰島素製劑的普及度。隨著越來越多的醫療器材和製藥公司參與合作，這些技術正在簡化治療，減少給藥錯誤，改善患者的生活質量，並支持市場成長。 2024年8月，雅培與美敦力合作開發了基於雅培FreeStyle Libre技術的整合式連續血糖監測 (CGM) 系統。該系統將與美敦力的自動胰島素輸送系統和智慧胰島素筆系統結合，自動調整胰島素劑量。 CGM感測器將由雅培設計，並由美敦力銷售。

轉向個人化強化胰島素治療

糖尿病治療中對精準醫療的需求日益增長，這增加了速效胰島素在個人化治療方案中的重要性。醫生現在對能夠密切反映生理性胰島素分泌的強化胰島素治療很感興趣，尤其是對於使用胰島素的第一型糖尿病患者和第2型糖尿病患者。速效胰島素是這項策略的關鍵組成部分，能夠調節餐後血糖升高。此外，人們越來越意識到更嚴格的血糖控制對患者的益處，包括降低長期併發症的風險。以患者為中心的治療方法以及越來越多地使用動態血糖監測 (CGM) 數據來指導胰島素給藥，正在推動全球對速效胰島素的需求。 2024 年 11 月，InsuJet 無針設備將採用創新的噴射注射技術，無需針頭即可精準注射胰島素。它還能減輕針頭注射帶來的不適和焦慮。

速效胰島素市場的障礙

速效胰島素成本高

速效胰島素市場的主要障礙之一是成本高昂，尤其是在醫療保險覆蓋率較低的國家。賴脯胰島素和門冬胰島素的價格通常高於人類胰島素，這使得中低收入國家的患者無法獲得它們。即使在美國這樣的已開發市場，胰島素的供應仍然是一個主要問題，引發了社會壓力和政策行動。生物相似藥正逐漸進入市場以解決價格問題，但監管障礙和品牌影響力仍然是阻礙因素。過高的價格通常會導致胰島素配給不足、依從性差以及不良的健康後果，從而損害服務欠缺地區的市場前景。

本報告提供全球速效型胰島素市場相關調查，成長推動因素與課題，各市場區隔的分析，主要企業的分析等資訊。

目錄

第1章 簡介

第2章 調查和調查手法

第3章 摘要整理

第4章 市場動態

• 成長促進因素
• 課題
• 機會

第5章 全球速效型胰島素市場

第6章 市場佔有率分析

• 各產品
• 各適應症
• 各流通管道
• 各國

第7章 產品

• Lispro胰島素
• Aspart胰島素
• Glulisine胰島素

第8章 適應症

• 第一型糖尿病
• 第二型糖尿病

第9章 流通管道

• 醫院藥局
• 藥妝店，藥局
• 網路商店

第10章 國家

• 北美
  • 美國
  • 加拿大
• 歐洲
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 比利時
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 泰國
  • 馬來西亞
  • 印尼
  • 紐西蘭
• 南美
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東·非洲
  • 南非
  • 沙烏地阿拉伯
  • 土耳其
  • 阿拉伯聯合大公國

第11章 波特的五力分析

第12章 SWOT分析

第13章 主要企業的分析

• Adocia
• Biocon Limited
• Eli Lilly and Company
• Gan & Lee Pharmaceuticals Co. Ltd.
• Geropharm
• MannKind Corporation
• Merck & Co. Inc.
• Novo Nordisk A/S
• Sanofi S.A.
• Wockhardt Ltd.

Rapid Acting Insulin Market Trends & Summary

The Rapid Acting Insulin Market valued at USD 7.71 billion in 2024 is anticipated to grow strongly to USD 11.77 billion by 2033. This growth represents a strong compound annual growth rate (CAGR) of 4.81% from 2025 to 2033."

The report Rapid Acting Insulin Market Forecast covers by Product (Lispro Insulin, Aspart Insulin, Glulisine Insulin), Indication (Type 1 Diabetes, Type 2 Diabetes), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Stores), Country and Company Analysis 2025-2033.

The growth is supported by growing diabetes prevalence, the need for proper glycemic control, and improved insulin delivery technologies.

Rapid Acting Insulin Market Outlooks

Rapid acting insulin, or fast-acting insulin, starts to act between 10 to 30 minutes after injection, peaks within 1 to 3 hours, and lasts for as long as 5 hours. It is mostly utilized to control postprandial blood glucose surges in people with diabetes, primarily Type 1 and complicated Type 2 diabetes. Examples include insulin lispro, insulin aspart, and insulin glulisine.

These insulins are commonly used in combination with long-acting insulins in a basal-bolus regimen to more closely approximate the body's own insulin secretion. Their rapid onset makes them particularly suitable for flexible meal scheduling and improved postprandial glucose control. Globally, rapid-acting insulin is increasingly popular because of the growing number of diabetes cases, rising use of insulin pens and pumps, and increased awareness of early and effective diabetes care. Advancements in biosimilars and affordability programs are also improving worldwide access.

Growth Drivers for the Rapid Acting Insulin Market

Increasing Global Prevalence of Diabetes

The rising global diabetes burden, particularly Type 1 and Type 2, is a key driver for the rapid acting insulin market. As per the International Diabetes Federation, more than 530 million adults lived with diabetes in 2023, and the number is expected to increase consistently. This increase in diabetic patient populations is directly attributed to increasing demand for effective, fast-acting insulin treatments to manage postprandial blood glucose. As more patients need accurate insulin dosing, healthcare professionals are prescribing rapid acting insulin as part of personalized treatment plans. Governments and healthcare systems are also investing more in diabetes awareness and treatment facilities, further propelling market growth. As of recent projections, more than 537 million adults have diabetes worldwide, and this number is estimated to reach 700 million by 2045.

Advances in Insulin Delivery Devices

Technological advancements in insulin pens, pumps, and continuous glucose monitoring systems have greatly improved the convenience and effectiveness of rapid acting insulin. Current delivery devices offer patients precise, easy dosing, lowering the risk of hypoglycemia and maximizing glycemic control. These developments have aided increased uptake of rapid acting insulins by younger and more technologically advanced patients, along with better adherence to treatment. Compatibility with diabetes management apps and smart insulin pens also enhances the popularity of these insulins. With more device and pharmaceutical companies coming together, these technologies are simplifying therapy, decreasing administration errors, and improving the quality of life for patients, thereby supporting market growth. Aug 2024, Abbott and Medtronic have partnered to create an integrated continuous glucose monitoring (CGM) system based on Abbott's FreeStyle Libre technology. The system will be combined with Medtronic's automated insulin delivery and smart insulin pen systems to automatically adjust insulin doses. Abbott will design the CGM sensor and Medtronic will sell it.

Shift Toward Personalized and Intensive Insulin Therapy

The growing need for precision medicine in the management of diabetes has raised the level of importance for rapid acting insulin in individualized treatment regimens. Physicians are now concerned with intensive insulin therapy that reflects physiological insulin release closely, specifically for Type 1 diabetics and Type 2 diabetic patients who use insulin. Rapid acting insulin is a pivotal component of the strategy, regulating blood sugar excursions following food intake. In addition, awareness of patient benefits for tighter glycemic control, such as reduced risks of long-term complications, is growing. Coupled with patient-focused treatment approaches and increased application of CGM data to direct insulin dosing, demand for rapid acting insulin is being driven globally. Nov 2024, The InsuJet Needle-free Device harnesses innovative jet injection technology to administer accurate insulin doses without the use of needles. It reduces discomfort and anxiety concerning needle injections.

Drawbacks of the Rapid Acting Insulin Market

High Cost of Rapid Acting Insulin

One of the major drawbacks in the market of rapid acting insulin is that it is too costly, especially in nations lacking widespread healthcare coverage. Insulin lispro and insulin aspart are usually priced above human insulin, making them unavailable to low- and middle-income countries' patients. Even in developed markets such as the U.S., the affordability of insulin remains a significant issue that triggers public pressure as well as policy action. Although biosimilars are gradually coming into the market to fix the problem of price, regulatory obstacles and brand strength continue to be limiting factors. Exorbitant prices usually result in high rates of insulin rationing, lowered compliance, and undesirable health consequences, defiling market potential in underserved areas.

Regulated and Cold Chain Requirements

Manufacture, approval, and distribution of rapid acting insulin demand compliance with strict regulatory controls and temperature-controlled supply. Sustaining the cold chain during the supply chain is essential to ensuring insulin effectiveness and potency. This creates logistics issues, especially in developing countries with poor infrastructure. The process of regulatory approval for biosimilars is complicated and takes time, delaying entry into market and competition. Companies have to spend a lot on R&D and clinical trials in order to satisfy safety and efficacy requirements. These supply and regulatory restrictions can reduce product availability, influence pricing strategies, and impede the timely launch of new or enhanced formulations in international markets.

Lispro Rapid Acting Insulin Market

Insulin lispro, a top rapid acting insulin analog, is commonly used for its rapid onset and consistent post-meal glucose control. It generally starts to work within 15 minutes and is favored by both Type 1 and insulin-dependent Type 2 diabetics. Lispro is commonly prescribed in basal-bolus therapy regimens and is pump-compatible. Its availability in biosimilar form has also helped see more adoption in cost-conscious markets. Global pharmaceutical giants are making improvements in lispro formulations for improved stability and convenience of use. Continuing research and growing demand for rapid-acting alternatives in both hospital and outpatient environments continue to drive market growth.

Aspart Rapid Acting Insulin Market

Insulin aspart is a widely used rapid acting insulin analog characterized by its fast absorption and onset of action. Most commonly used in combination therapy with long-acting insulins, aspart has a vital role in controlling postprandial glucose levels. Both the original and biosimilar versions of aspart are widely available, rendering it possible to be implemented across different healthcare systems. The effectiveness, safety profile, and ease of use through insulin pens and pumps all contribute to aspart being favored by endocrinologists and diabetes health care professionals. While global diabetes incidence increases, demand for aspart grows, especially in markets where healthcare access and reimbursement of analog insulins are enhancing, driving consistent market growth.

Type 2 Diabetes Rapid Acting Insulin Market

Increase in prevalence of insulin-dependent Type 2 diabetes is greatly driving demand for rapid acting insulin. As the disease progresses in severity, most patients need post-meal insulin to get good glycemic control. Rapid acting insulin assists in controlling glucose peaks and lowering HbA1c levels in these patients, frequently as part of a multiple daily injection (MDI) regimen. With the increase in obesity rates and lack of physical activity, particularly in middle-income nations, the population of Type 2 patients who are moving towards insulin therapy is on the rise. Patient education regarding the advantages of analog insulins and more expansive reimbursement practices are also accelerating the uptake of rapid acting insulin in this group.

Rapid Acting Insulin Hospital Pharmacies Market

Hospital pharmacies have an important function to play in distributing rapid acting insulin, especially in newly diagnosed cases of diabetes or patients on inpatient status. These pharmacies guarantee stock availability of crucial insulin products, such as lispro and aspart, for quick glycemic control. Within hospitals, rapid-acting insulin is typically used in surgical recovery room, emergency room, or intensive care settings in which tight control of blood sugars is required. Additionally, caregivers depend on the hospital pharmacy to have immediate availability of specialty insulin pens and vials. With hospitals increasingly dealing with diabetes as a comorbidity in the management of various conditions, the channel will likely continue to dominate its robust share in the upcoming years.

Rapid Acting Insulin Online Retailers Market

Online pharmacies and online retail websites are becoming increasingly popular for the delivery of insulin, especially among urban and tech-literate populations. These websites are convenient, priced competitively, and easily provide branded and biosimilar rapid acting insulin products. Doorstep delivery, refill reminders, and teleconsultations are a boon to patients. As the COVID-19 pandemic unfolded, online purchases of insulin gained traction, underscoring its increasing significance. With growing digital health infrastructure and improved cold chain logistics, online sales channels are likely to keep on increasing. Governments and private sector players are also investing in secure, regulated e-pharmacy platforms to provide safe distribution, further solidifying the channel's significance in the insulin ecosystem.

United States Rapid Acting Insulin Market

The U.S. is among the most significant markets for rapid acting insulin with a high prevalence of diabetes, well-developed healthcare infrastructure, and early uptake of insulin delivery technology. Gaining access with increasing availability of biosimilar insulins and price reforms is becoming better. The major players are also working on bringing ultra-rapid formulations to the market to address demand from patients for improved control of postprandial levels and convenience. The FDA has approved Merilog (insulin-aspart-szjj) as a biosimilar to NovoLog (insulin aspart), and it is the first rapid-acting insulin biosimilar in the US. Effective February 14, 2025, this approval is intended to enhance patient access to rapid-acting insulin therapy and is available in both prefilled pens and multiple-dose vials.

France Rapid Acting Insulin Market

France boasts a robust healthcare system with clearly defined reimbursement policies that facilitate access to rapid acting insulin. The market is aided by early diagnosis rates, extensive diabetes education, and uptake of insulin delivery technologies such as pumps and pens. Government support for biosimilars is enhancing affordability. Moreover, France's emphasis on innovation and clinical research guarantees a constant flow of new treatments, promoting long-term market growth.

India Rapid Acting Insulin Market

India's rapid acting insulin market is growing driven by increasing prevalence of diabetes and growing awareness regarding contemporary insulin therapy. Urban communities are more prone to opt for rapid-acting insulin, aided by enhanced access through private hospitals and web platforms. Although affordability issues persist, the emergence of biosimilars and government schemes are improving availability in urban as well as semi-urban regions. Feb 2025, Cipla has obtained regulatory clearance to launch Afrezza, the world's first ultra-rapid-acting inhaled insulin, in India, a groundbreaking development in the management of diabetes.

Saudi Arabia Rapid Acting Insulin Market

The rapid acting insulin market of Saudi Arabia is increasing progressively with growth in diabetes treatment rates and increased government investment in healthcare facilities. Public and private initiatives are directed towards increasing access to advanced insulin therapies, such as analogs like lispro and aspart. Penetration of insulin pens and digital monitoring devices is increasing treatment adherence on a large scale. Educational campaigns and subsidized pricing programs are also enhancing insulin access throughout the regions. September 2024, Biocon has collaborated with Tabuk Pharmaceuticals for the commercialization of GLP-1 products for treating diabetes and weight control in the Middle East.

Rapid Acting Insulin Market Segments

Product

1. Lispro Insulin

2. Aspart Insulin

3. Glulisine Insulin

Indication

1. Type 1 Diabetes

2. Type 2 Diabetes

Distribution Channel

1. Hospital Pharmacies

2. Drug Stores and Retail Pharmacies

3. Online Stores

Country

North America

1. United States

2. Canada

Europe

1. France

2. Germany

3. Italy

4. Spain

5. United Kingdom

6. Belgium

7. Netherlands

8. Turkey

Asia Pacific

1. China

2. Japan

3. India

4. Australia

5. South Korea

6. Thailand

7. Malaysia

8. Indonesia

9. New Zealand

Latin America

1. Brazil

2. Mexico

3. Argentina

Middle East & Africa

1. South Africa

2. Saudi Arabia

3. UAE

All the key players have been covered from 4 Viewpoints:

• Overview
• Key Persons
• Recent Development
• Revenue

Company Analysis

1. Alcon Inc.

2. Bausch Health Companies Inc.

3. Carl Zeiss Meditec AG

4. EssilorLuxottica SA

5. HAAG-Streit Group

6. Hoya Corporation

7. Johnson and Johnson

8. Nidek Co. Ltd

9. Topcon Corporation

10. Ziemer Ophthalmic Systems AG

Table of Contents

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

• 4.1 Growth Drivers
• 4.2 Challenges
• 4.3 Opportunities

5. Global Rapid Acting Insulin Market

6. Market Share Analysis

• 6.1 By Product
• 6.2 By Indication
• 6.3 By Distribution Channel
• 6.4 By Countries

7. Product

• 7.1 Lispro Insulin
• 7.2 Aspart Insulin
• 7.3 Glulisine Insulin

8. Indication

• 8.1 Type 1 Diabetes
• 8.2 Type 2 Diabetes

9. Distribution Channel

• 9.1 Hospital Pharmacies
• 9.2 Drug Stores and Retail Pharmacies
• 9.3 Online Stores

10. Countries

• 10.1 North America
  • 10.1.1 United States
  • 10.1.2 Canada
• 10.2 Europe
  • 10.2.1 France
  • 10.2.2 Germany
  • 10.2.3 Italy
  • 10.2.4 Spain
  • 10.2.5 United Kingdom
  • 10.2.6 Belgium
  • 10.2.7 Netherland
• 10.3 Asia Pacific
  • 10.3.1 China
  • 10.3.2 Japan
  • 10.3.3 India
  • 10.3.4 Australia
  • 10.3.5 South Korea
  • 10.3.6 Thailand
  • 10.3.7 Malaysia
  • 10.3.8 Indonesia
  • 10.3.9 New Zealand
• 10.4 Latin America
  • 10.4.1 Brazil
  • 10.4.2 Mexico
  • 10.4.3 Argentina
• 10.5 Middle East & Africa
  • 10.5.1 South Africa
  • 10.5.2 Saudi Arabia
  • 10.5.3 Turkey
  • 10.5.4 UAE

11. Porter's Five Forces Analysis

• 11.1 Bargaining Power of Buyers
• 11.2 Bargaining Power of Suppliers
• 11.3 Degree of Rivalry
• 11.4 Threat of New Entrants
• 11.5 Threat of Substitutes

12. SWOT Analysis

• 12.1 Strength
• 12.2 Weakness
• 12.3 Opportunity
• 12.4 Threat

13. Key Players Analysis

• 13.1 Adocia
  • 13.1.1 Overview
  • 13.1.2 Key Persons
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Development & Strategies
  • 13.1.5 Revenue Analysis
• 13.2 Biocon Limited
  • 13.2.1 Overview
  • 13.2.2 Key Persons
  • 13.2.3 Product Portfolio
  • 13.2.4 Recent Development & Strategies
  • 13.2.5 Revenue Analysis
• 13.3 Eli Lilly and Company
  • 13.3.1 Overview
  • 13.3.2 Key Persons
  • 13.3.3 Product Portfolio
  • 13.3.4 Recent Development & Strategies
  • 13.3.5 Revenue Analysis
• 13.4 Gan & Lee Pharmaceuticals Co. Ltd.
  • 13.4.1 Overview
  • 13.4.2 Key Persons
  • 13.4.3 Product Portfolio
  • 13.4.4 Recent Development & Strategies
  • 13.4.5 Revenue Analysis
• 13.5 Geropharm
  • 13.5.1 Overview
  • 13.5.2 Key Persons
  • 13.5.3 Product Portfolio
  • 13.5.4 Recent Development & Strategies
  • 13.5.5 Revenue Analysis
• 13.6 MannKind Corporation
  • 13.6.1 Overview
  • 13.6.2 Key Persons
  • 13.6.3 Product Portfolio
  • 13.6.4 Recent Development & Strategies
  • 13.6.5 Revenue Analysis
• 13.7 Merck & Co. Inc.
  • 13.7.1 Overview
  • 13.7.2 Key Persons
  • 13.7.3 Product Portfolio
  • 13.7.4 Recent Development & Strategies
  • 13.7.5 Revenue Analysis
• 13.8 Novo Nordisk A/S
  • 13.8.1 Overview
  • 13.8.2 Key Persons
  • 13.8.3 Product Portfolio
  • 13.8.4 Recent Development & Strategies
  • 13.8.5 Revenue Analysis
• 13.9 Sanofi S.A.
  • 13.9.1 Overview
  • 13.9.2 Key Persons
  • 13.9.3 Product Portfolio
  • 13.9.4 Recent Development & Strategies
  • 13.9.5 Revenue Analysis
• 13.10 Wockhardt Ltd.
  • 13.10.1 Overview
  • 13.10.2 Key Persons
  • 13.10.3 Product Portfolio
  • 13.10.4 Recent Development & Strategies
  • 13.10.5 Revenue Analysis